Tissue Acquisition And Cellular/Molecular Analysis Shared Resource (TACMASR)

组织采集和细胞/分子分析共享资源 (TACMASR)

• 批准号: 10676928
• 负责人: Yana Zavros
• 金额: $ 23.72万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10676928
• 关键词: 3-Dimensional; Arizona; Biological Markers; Cancer Center; Cancer Center Support Grant; Cells; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Collection; Coupled; DNA Sequence Alteration; Development; Dimensions; Disease; Disease Progression; Doctor of Philosophy; Early Diagnosis; Early treatment; Education; Fostering; Frozen Sections; Funding; Gender; Generations; Genes; Genome; Goals; Grant; Health Services Research; Hematoxylin and Eosin Staining Method; Histology; Human; Image; Immune; Implant; Individual; Laboratories; Life Style; Malignant Neoplasms; Methods; Microscopy; Molecular Analysis; Morphology; Mutation; Organoids; Paraffin Embedding; Pathology; Patients; Pre-Clinical Model; Prevention; Process; Protocols documentation; Publications; Research; Research Design; Research Personnel; Resource Sharing; Resources; Sampling; Services; Signal Pathway; Specimen; Stains; Technology; Testing; Therapeutic; Three-dimensional analysis; Tissue Banks; Tissue Sample; Tissues; Training; Translational Research; Universities; University resources; animal tissue; anticancer research; biobank; cancer therapy; comorbidity; digital; drug discovery; epigenome; human disease; human tissue; innovation; insight; instrumentation; member; microbiome; molecular targeted therapies; mouse model; novel therapeutics; personalized approach; personalized cancer therapy; specific biomarkers; targeted biomarker; targeted treatment; three dimensional cell culture; tool; treatment response; tumor

TISSUE ACQUISITION & CELLULAR/MOLECULAR ANALYSIS: ABSTRACT Personalized treatment of cancer is rapidly becoming a standard practice. Several factors contribute to the uniqueness of a patient, including the individual’s genome, the genome and epigenome of the cancer, disease presentation, gender, exposures, lifestyle, microbiome, and other comorbidities. The identification of specific biomarkers, signaling pathways, immune cell signatures and genetic mutations within tumors underlies molecular targeted therapies and new insights into cancer treatment. Projects require tissue samples of human tumors, which may be implanted in mouse models or used for the generation of organotypic cultures that duplicate the human disease progression and response to treatment. New drug treatments will first be tested in these preclinical models using patient samples before developed therapeutic approaches reach clinical trials. In addition, deciphering genetic alterations and aberrant and tumor-related genes are used for biomarkers for targeted therapies that is unique to that patient. The overall goal of the Tissue Acquisition & Cellular/Molecular Analysis Shared Resource (TACMASR) is to foster individualized approaches for the early detection and therapy of cancers utilizing a new dimension of research pathology for biomarker/drug discovery, digital and spatial imaging, and innovative morphological analysis of 3D cultures. Through continued emphasis on advancing clinical and translational research and increasing collaborations among basic and clinical investigators, TACMASR serves as a centralized resource, providing University of Arizona Cancer Center (UACC) Members with access to clinically annotated, high-quality human specimens. TACMASR offers a comprehensive biorepository coupled with advanced human and animal tissue analysis using state-of-the art microscopy, 3D organotypic cultures, and expert analysis and interpretation of results by well trained staff. The Specific Aims of TACMASR are to: (1) provide biospecimens with a seamless process for the collection, processing, banking, and distribution of human tissues; (2) support a full service research histology laboratory that offers routine and specialized paraffin embedding, sectioning, automated hematoxylin and eosin staining, frozen sectioning, and a large selection of special stains; and (3) develop new protocols and state-of-the-art technologies to meet the special needs of requesting investigators and foster individualized approaches for the early detection and therapy of cancers. In CY20, TACMASR provided services to 81 unique users (53% UACC Members). Services since 2016 have contributed to 47 publications by UACC Members and 29 grants.

组织采集和细胞/分子分析：摘要 癌症的个性化治疗正在迅速成为一种标准做法。多个因素有助于 患者的独特性，包括个体的基因组、癌症的基因组和表观基因组、疾病 表现、性别、暴露、生活方式、微生物组和其他合并症。确定具体 肿瘤内的生物标志物、信号传导通路、免疫细胞特征和基因突变 分子靶向治疗和癌症治疗的新见解。项目需要人体组织样本 肿瘤，其可植入小鼠模型中或用于产生器官型培养物， 复制人类疾病进展和对治疗的反应。新的药物治疗将首先在 这些临床前模型在开发的治疗方法进入临床试验之前使用患者样品。 此外，破译遗传改变和异常及肿瘤相关基因被用作生物标志物， 针对该患者的独特靶向治疗。组织采集和细胞/分子的总体目标 分析共享资源（TACMASR）是为了促进早期发现和 利用生物标志物/药物发现的研究病理学的新维度进行癌症治疗， 空间成像和创新的3D文化形态分析。继续注重 推进临床和转化研究，增加基础和临床之间的合作 研究人员，TACMASR作为一个集中的资源，提供亚利桑那大学癌症中心 （UACC）成员可以获得临床注释的高质量人体标本。TACMASR提供了一个 全面的生物储存库，结合先进的人类和动物组织分析， 显微镜、3D器官型培养以及训练有素的工作人员进行的专家分析和结果解释。的 TACMASR的具体目标是：（1）为生物标本的采集提供无缝流程， 处理、储存和分发人体组织;（2）支持全方位服务的研究组织学实验室 提供常规和专门的石蜡包埋、切片、自动苏木精和伊红染色， 冷冻切片和大量特殊染色剂;（3）开发新的方案和最先进的技术 技术，以满足提出请求的调查人员的特殊需要， 癌症的早期检测和治疗。在CY 20，TACMASR为81个独立用户提供了服务（53% UACC 成员）。自2016年以来，UACC成员的服务为47份出版物和29份赠款做出了贡献。